308386-23-4

Basic information

• Product Name: 1-Pyrrolidinecarboxylic acid, 3-[4-(trifluoromethyl)phenoxy]-, 1,1-dimethylethyl ester
• CAS NO: 308386-23-4
• Molecular Formula: C16H20F3NO3
• Molecular Weight: 331.335
• Mol File: 308386-23-4.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-Pyrrolidinecarboxylic acid, 3-[4-(trifluoromethyl)phenoxy]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinecarboxylic acid, 3-[4-(trifluoromethyl)phenoxy]-, 1,1-dimethylethyl ester(308386-23-4)
• EPA Substance Registry System: 1-Pyrrolidinecarboxylic acid, 3-[4-(trifluoromethyl)phenoxy]-, 1,1-dimethylethyl ester(308386-23-4)

Safety Data

• Hazardous Substances Data: 308386-23-4(Hazardous Substances Data)

Usage

Class

1-Pyrrolidinecarboxylic acid, 3-[4-(trifluoromethyl)phenoxy]-, 1,1-dimethylethyl ester belongs to the class of pyrrolidinecarboxylic acids.

Medicinal chemistry use

It is commonly used in medicinal chemistry as a building block for the synthesis of pharmaceutical products.

Ability to mimic natural amino acids

It has the ability to mimic natural amino acids, which makes it useful in the synthesis of pharmaceutical products.

Biological activity

It has been found to exhibit potential biological activity, including anticancer and antiviral properties.

Industrial use

It is used in some industries as an intermediate for the production of various chemicals and drugs.

Safety precautions

Proper handling and safety precautions should be taken when working with 1-Pyrrolidinecarboxylic acid, 3-[4-(trifluoromethyl)phenoxy]-, 1,1-dimethylethyl ester to prevent any potential hazards.

Upstream product

• 402-45-9 4-hydroxybenzotrifluoride 
• 103057-44-9 N-(tert-butoxycarbonyl)-3-hydroxypyrrolidine 

Downstream Products

• 308386-24-5 3-(4-(trifluoromethyl)phenoxy)pyrrolidine 

Relevant articles and documents

PYRIDINE AMIDE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

The invention relates pyridine amide derivative of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently hydrogen, linear o branched (C1-C3)alkyl or joined together they form a cyclopropyl ring; R is independently selected from the group consisting of halogens and trifluoromethyl and p is 1, 2 or 3; A is C or N; E is a group of formula (B) or (C), wherein B is C(O)OH, C(O)O(C1-C3)alkyl, and C is selected from the group consisting of formula (I) m is 1,2 or 3, n is 0 or 1, W is —O—, —O(C1-C3 alkyl)-; —(C1-C3 alkyl)O—; —C(O)—; —C(═N—O(C1-C3 alkyl))-; —NH— or —NH(C1-C3alkyl)-; Ar is phenyl, optionally substituted with one or more substituents selected from the group consisting of halogen, trifluoromethyl, trifluoromethoxy, methyl, —NH(C1-C3alkyl)-; —N(C1-C3alkyl)(C1-C3alkyl)-, a from 5 to 7 membered heterocyclic ring containing one nitrogen atom which is covalently bonded to Ar and optionally containing one or two heteroatoms selected from N, O and S; and a 5- or 6-membered heteroaromatic ring containing 1 to 3 heteroatoms selected from S, O e N, such heteroaromatic ring being substituted with one or two substituents selected from the group consisting of (C1-C3)alkyl, (C3-C5)cycloalkyloxy, (C1-C3)alkylcarbonyl. The compounds of the invention could be used for manufacturing a medicament for the treatment of pathologies which require the use of an antagonist of the EP4 receptor, such as the treatment of acute and chronic pain, inflammatory pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, endometriosis and migraine.

Substituted phenyl methanone derivatives

The present invention relates to compounds of formula I wherein R1, R2, R3, n, and m, are as defined in the specification and to pharmaceutically acceptable acid addition salts thereof. These compounds are good inhibitors